| Dr Janet Eileen Morgan, MD | |
|
1520 E 23rd St, Suite I, Independence, MO 64055-1657 | |
| (816) 836-4740 | |
| (816) 836-4745 |
| Full Name | Dr Janet Eileen Morgan |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 48 Years |
| Location | 1520 E 23rd St, Independence, Missouri |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063403525 | NPI | - | NPPES |
| 1063403525 | Medicaid | MO | |
| 200592750A | Medicaid | KS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 35847 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| One Community Hospice | Kansas city, MO | Hospice |
| Cass Regional Medical Center | Harrisonville, MO | Hospital |
| Meadow View Of Harrisonville Health & Rehab | Harrisonville, MO | Nursing home |
| Crown Care Center | Harrisonville, MO | Nursing home |
| Gregory Ridge Health Care Center | Kansas city, MO | Nursing home |
| Medicalodges Leavenworth | Leavenworth, KS | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Barnes Health Care Management Group Llc | 1759441447 | 48 |
| Barnes Health Llc | 9739541301 | 47 |
| Barnes Health Care Management Group Llc | 1759441447 | 48 |
| Barnes Health Llc | 9739541301 | 47 |
News Archive
Accentia Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Revimmune, the Company's proprietary system-of-care based on high-dose administration of Cytoxan, for the treatment of two autoimmune disease indications, systemic sclerosis and autoimmune hemolytic anemia.
The mechanism by which a herpes virus invades cells has remained a mystery to scientists, but now research from Tufts University and the University of Pennsylvania reveals the unusual structure of a key member of the protein complex that allows a herpes virus to invade cells.The new map details an essential piece of the herpes virus "cell-entry machinery," providing scientists with a new target for antiviral drugs.
Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that it presented information to members of a U.S. Food and Drug Administration (FDA) Advisory Committee on the New Drug Application and proposed Risk Evaluation and Mitigation Strategy (REMS) program for EXALGOTM (hydromorphone HCl extended release) tablets, an opioid formulation.
Over the past weeks, health officials around the globe traced and advised suspected contacts of people with the coronavirus disease (COVID-19) to isolate themselves for 14 days, the incubation period of the disease.
› Verified 3 days ago
| Entity Name | Barnes Health Care Management Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396999686 PECOS PAC ID: 1759441447 Enrollment ID: O20081126000113 |
News Archive
Accentia Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Revimmune, the Company's proprietary system-of-care based on high-dose administration of Cytoxan, for the treatment of two autoimmune disease indications, systemic sclerosis and autoimmune hemolytic anemia.
The mechanism by which a herpes virus invades cells has remained a mystery to scientists, but now research from Tufts University and the University of Pennsylvania reveals the unusual structure of a key member of the protein complex that allows a herpes virus to invade cells.The new map details an essential piece of the herpes virus "cell-entry machinery," providing scientists with a new target for antiviral drugs.
Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that it presented information to members of a U.S. Food and Drug Administration (FDA) Advisory Committee on the New Drug Application and proposed Risk Evaluation and Mitigation Strategy (REMS) program for EXALGOTM (hydromorphone HCl extended release) tablets, an opioid formulation.
Over the past weeks, health officials around the globe traced and advised suspected contacts of people with the coronavirus disease (COVID-19) to isolate themselves for 14 days, the incubation period of the disease.
› Verified 3 days ago
| Entity Name | National Medical Partners Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598126559 PECOS PAC ID: 5294033072 Enrollment ID: O20160412001476 |
News Archive
Accentia Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Revimmune, the Company's proprietary system-of-care based on high-dose administration of Cytoxan, for the treatment of two autoimmune disease indications, systemic sclerosis and autoimmune hemolytic anemia.
The mechanism by which a herpes virus invades cells has remained a mystery to scientists, but now research from Tufts University and the University of Pennsylvania reveals the unusual structure of a key member of the protein complex that allows a herpes virus to invade cells.The new map details an essential piece of the herpes virus "cell-entry machinery," providing scientists with a new target for antiviral drugs.
Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that it presented information to members of a U.S. Food and Drug Administration (FDA) Advisory Committee on the New Drug Application and proposed Risk Evaluation and Mitigation Strategy (REMS) program for EXALGOTM (hydromorphone HCl extended release) tablets, an opioid formulation.
Over the past weeks, health officials around the globe traced and advised suspected contacts of people with the coronavirus disease (COVID-19) to isolate themselves for 14 days, the incubation period of the disease.
› Verified 3 days ago
| Entity Name | Sigma Haggerty Medical Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699136655 PECOS PAC ID: 9537467386 Enrollment ID: O20160412002592 |
News Archive
Accentia Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Revimmune, the Company's proprietary system-of-care based on high-dose administration of Cytoxan, for the treatment of two autoimmune disease indications, systemic sclerosis and autoimmune hemolytic anemia.
The mechanism by which a herpes virus invades cells has remained a mystery to scientists, but now research from Tufts University and the University of Pennsylvania reveals the unusual structure of a key member of the protein complex that allows a herpes virus to invade cells.The new map details an essential piece of the herpes virus "cell-entry machinery," providing scientists with a new target for antiviral drugs.
Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that it presented information to members of a U.S. Food and Drug Administration (FDA) Advisory Committee on the New Drug Application and proposed Risk Evaluation and Mitigation Strategy (REMS) program for EXALGOTM (hydromorphone HCl extended release) tablets, an opioid formulation.
Over the past weeks, health officials around the globe traced and advised suspected contacts of people with the coronavirus disease (COVID-19) to isolate themselves for 14 days, the incubation period of the disease.
› Verified 3 days ago
| Entity Name | City Medical Partners Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285095315 PECOS PAC ID: 5991003659 Enrollment ID: O20160412002862 |
News Archive
Accentia Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Revimmune, the Company's proprietary system-of-care based on high-dose administration of Cytoxan, for the treatment of two autoimmune disease indications, systemic sclerosis and autoimmune hemolytic anemia.
The mechanism by which a herpes virus invades cells has remained a mystery to scientists, but now research from Tufts University and the University of Pennsylvania reveals the unusual structure of a key member of the protein complex that allows a herpes virus to invade cells.The new map details an essential piece of the herpes virus "cell-entry machinery," providing scientists with a new target for antiviral drugs.
Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that it presented information to members of a U.S. Food and Drug Administration (FDA) Advisory Committee on the New Drug Application and proposed Risk Evaluation and Mitigation Strategy (REMS) program for EXALGOTM (hydromorphone HCl extended release) tablets, an opioid formulation.
Over the past weeks, health officials around the globe traced and advised suspected contacts of people with the coronavirus disease (COVID-19) to isolate themselves for 14 days, the incubation period of the disease.
› Verified 3 days ago
| Entity Name | Regional Medical Partners, P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366803405 PECOS PAC ID: 8022316256 Enrollment ID: O20160422000667 |
News Archive
Accentia Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Revimmune, the Company's proprietary system-of-care based on high-dose administration of Cytoxan, for the treatment of two autoimmune disease indications, systemic sclerosis and autoimmune hemolytic anemia.
The mechanism by which a herpes virus invades cells has remained a mystery to scientists, but now research from Tufts University and the University of Pennsylvania reveals the unusual structure of a key member of the protein complex that allows a herpes virus to invade cells.The new map details an essential piece of the herpes virus "cell-entry machinery," providing scientists with a new target for antiviral drugs.
Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that it presented information to members of a U.S. Food and Drug Administration (FDA) Advisory Committee on the New Drug Application and proposed Risk Evaluation and Mitigation Strategy (REMS) program for EXALGOTM (hydromorphone HCl extended release) tablets, an opioid formulation.
Over the past weeks, health officials around the globe traced and advised suspected contacts of people with the coronavirus disease (COVID-19) to isolate themselves for 14 days, the incubation period of the disease.
› Verified 3 days ago
| Entity Name | Barnes Health Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275219073 PECOS PAC ID: 9739541301 Enrollment ID: O20230814002158 |
News Archive
Accentia Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Revimmune, the Company's proprietary system-of-care based on high-dose administration of Cytoxan, for the treatment of two autoimmune disease indications, systemic sclerosis and autoimmune hemolytic anemia.
The mechanism by which a herpes virus invades cells has remained a mystery to scientists, but now research from Tufts University and the University of Pennsylvania reveals the unusual structure of a key member of the protein complex that allows a herpes virus to invade cells.The new map details an essential piece of the herpes virus "cell-entry machinery," providing scientists with a new target for antiviral drugs.
Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that it presented information to members of a U.S. Food and Drug Administration (FDA) Advisory Committee on the New Drug Application and proposed Risk Evaluation and Mitigation Strategy (REMS) program for EXALGOTM (hydromorphone HCl extended release) tablets, an opioid formulation.
Over the past weeks, health officials around the globe traced and advised suspected contacts of people with the coronavirus disease (COVID-19) to isolate themselves for 14 days, the incubation period of the disease.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Janet Eileen Morgan, MD 1520 E 23rd St S, Suite I, Independence, MO 64055-1657 Ph: (816) 836-4740 | Dr Janet Eileen Morgan, MD 1520 E 23rd St, Suite I, Independence, MO 64055-1657 Ph: (816) 836-4740 |
News Archive
Accentia Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Revimmune, the Company's proprietary system-of-care based on high-dose administration of Cytoxan, for the treatment of two autoimmune disease indications, systemic sclerosis and autoimmune hemolytic anemia.
The mechanism by which a herpes virus invades cells has remained a mystery to scientists, but now research from Tufts University and the University of Pennsylvania reveals the unusual structure of a key member of the protein complex that allows a herpes virus to invade cells.The new map details an essential piece of the herpes virus "cell-entry machinery," providing scientists with a new target for antiviral drugs.
Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that it presented information to members of a U.S. Food and Drug Administration (FDA) Advisory Committee on the New Drug Application and proposed Risk Evaluation and Mitigation Strategy (REMS) program for EXALGOTM (hydromorphone HCl extended release) tablets, an opioid formulation.
Over the past weeks, health officials around the globe traced and advised suspected contacts of people with the coronavirus disease (COVID-19) to isolate themselves for 14 days, the incubation period of the disease.
› Verified 3 days ago
Dr. Michael G Wells, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 11605 E 23rd St S, Independence, MO 64050 Phone: 816-579-6891 | |
Dr. Lewis Rosenblatt, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4621 S Shrank Dr, Suite B, Independence, MO 64055 Phone: 816-229-3200 Fax: 816-503-8325 | |
Katherine Field, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 19600 E 39th St S, Independence, MO 64057 Phone: 913-222-9779 Fax: 816-312-4380 | |
Ho Lau, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 19600 E 39th St S, Independence, MO 64057 Phone: 913-222-9779 Fax: 816-312-4380 | |
Jennifer J Patterson, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4721 S Cliff Ave, Suite 200, Independence, MO 64055 Phone: 816-503-3700 Fax: 816-503-3704 | |
Katherine Suzanne Lee, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 12400 E Us Highway 40, Independence, MO 64055 Phone: 816-890-9507 Fax: 816-890-9516 |